Microbes and mucosal immune responses in asthma

The Lancet

Volumn 381, Issue 9869, 2013, Pages 861-873

  Hansel, Trevor T ^a   Johnston, Sebastian L ^a   Openshaw, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; ALPHA TOCOPHEROL; INTERLEUKIN 25; INTERLEUKIN 33; MONOCLONAL ANTIBODY; PATTERN RECOGNITION RECEPTOR; VITAMIN D; ZINC;

ALLERGIC ASTHMA; ALLERGIC REACTION; ASTHMA; ATOPY; BRONCHIOLITIS; BRONCHITIS; CHLAMYDOPHILA PNEUMONIAE; DEVELOPMENT; DISEASE TRANSMISSION; HAEMOPHILUS INFLUENZAE; HUMAN RHINOVIRUS; IMMUNE RESPONSE; INFLUENZA A; LYMPHOID CELL; MICROORGANISM; MUCOSAL IMMUNITY; MYCOPLASMA PNEUMONIAE; NATURAL KILLER CELL; PATHOGENESIS; PATHOPHYSIOLOGY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT MUCOSA; REVIEW; SECONDARY INFECTION; TH2 CELL; UMBILICAL CORD BLOOD; VIRUS LOAD; WHEEZING;

EID: 84874733216     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)62202-8     Document Type: Review

References (141)

1. Brahman SS. The global burden of asthma. Chest 2006; 130 (suppl 1): 4S-12S.
2. Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med 2006; 355: 2226-35.
3. Weinmayr G, Weiland SK, Björkstén B, et al. Atopic sensitization and the international variation of asthma symptom prevalence in children. Am J Respir Crit Care Med 2007; 176: 565-74.
4. Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347: 911-20.
5. Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention. Updated Dec, 2012. http://www. ginasthma.com (accessed Jan 4, 2013).
6. Akdis CA. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med 2012; 18: 736-49.
7. Zhang Y, Moffatt MF, Cookson WO. Genetic and genomic approaches to asthma: new insights for the origins. Curr Opin Pulm Med 2012; 18: 6-13.
8. Moffatt MF, Gut IG, Demenais F, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 2010; 363: 1211-21.
9. Durham AL, Wiegman C, Adcock IM. Epigenetics of asthma. Biochim Biophys Acta 2011; 1810: 1103-09.
10. Sly PD, Boner AL, Bjorksten B, et al. Early identification of atopy in the prediction of persistent asthma in children. Lancet 2008; 372: 1100-06.
11. Hawrylowicz C, Ryanna K. Asthma and allergy: the early beginnings. Nat Med 2010; 16: 274-75.
12. Holt PG, Sly PD. Viral infections and atopy in asthma pathogenesis: new rationales for asthma prevention and treatment. Nat Med 2012; 18: 726-35.
13. Catley MC, Coote J, Bari M, Tomlinson KL. Monoclonal antibodies for the treatment of asthma. Pharmacol Ther 2011; 132: 333-51.
14. Edwards MR, Bartlett NW, Hussell T, Openshaw P, Johnston SL. The microbiology of asthma. Nat Rev Microbiol 2012; 10: 459-71.
15. Bosch AATM, Biesbroek G, Trzcinski K, Sanders EAM, Bogaert D. Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog 2013; 9: 1-12.
16. Locksley RM. Asthma and allergic inflammation. Cell 2010; 140: 777-83.
17. Palm NW, Rosenstein RK, Medzhitov R. Allergic host defences. Nature 2012; 484: 465-72.
18. Brooks C, Pearce N, Douwes J. The hygiene hypothesis in allergy and asthma: an update. Curr Opin Allergy Clin Immunol 2013; 13: 70-77.
19. Essilfie AT, Simpson JL, Dunkley ML, et al. Combined Haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma. Thorax 2012; 67: 588-99.
20. Olszak T, An D, Zeissig S, et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012; 336: 489-93.
21. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486: 207-14.
22. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012; 489: 231-41.
23. Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science 2012; 336: 1262-67.
24. Han MK, Huang YJ, Lipuma JJ, et al. Significance of the microbiome in obstructive lung disease. Thorax 2012; 67: 456-63.
25. Huang YJ, Nelson CE, Brodie EL, et al. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol 2011; 127: 372-81.
26. McLoughlin RM, Mills KH. Influence of gastrointestinal commensal bacteria on the immune responses that mediate allergy and asthma. J Allergy Clin Immunol 2011; 127: 1097-107.
27. Bisgaard H, Li N, Bonnelykke K, et al. Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J Allergy Clin Immunol 2011; 128: 646-52.
28. Cox MJ, Huang YJ, Fujimura KE, et al. Lactobacillus casei abundance is associated with profound shifts in the infant gut microbiome. PLoS One 2010; 5: e8745.
29. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS ONE 2010; 5: e8578.
30. Ly NP, Litonjua A, Gold DR, Celedon JC. Gut microbiota, probiotics, and vitamin D: interrelated exposures influencing allergy, asthma, and obesity? J Allergy Clin Immunol 2011; 127: 1087-94.
31. Cameron EJ, McSharry C, Chaudhuri R, Farrow S, Thomson NC. Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clin Exp Allergy 2012; 42: 1302-12.
32. Busse WW, Lemanske RF Jr, Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet 2010; 376: 826-34.
33. Jackson DJ, Sykes A, Mallia P, Johnston SL. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol 2011; 128: 1165-74.
34. Holtzman MJ. Asthma as a chronic disease of the innate and adaptive immune systems responding to viruses and allergens. J Clin Invest 2012; 122: 2741-48.
35. Hussell T, Goulding J. Structured regulation of inflammation during respiratory viral infection. Lancet Infect Dis 2010; 10: 360-66.
36. Jartti T, Jartti L, Ruuskanen O, Soderlund-Venermo M. New respiratory viral infections. Curr Opin Pulm Med 2012; 18: 271-78.
37. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360: 588-98.
38. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375: 1545-55.
39. Prendergast AJ, Klenerman P, Goulder PJ. The impact of differential antiviral immunity in children and adults. Nat Rev Immunol 2012; 12: 636-48.
40. Bacharier LB, Cohen R, Schweiger T, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol 2012; 130: 91-100.
41. Sigurs N, Aljassim F, Kjellman B, et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010; 65: 1045-52.
42. Walsh EE, Falsey AR. Respiratory syncytial virus infection in adult populations. Infect Disord Drug Targets 2012; 12: 98-102.
43. Habibi MS, Openshaw PJ. Benefit and harm from immunity to respiratory syncytial virus: implications for treatment. Curr Opin Infect Dis 2012; 25: 687-94.
44. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, DeVincenzo JP. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis 2011; 204: 996-1002.
45. Lee HC, Headley MB, Loo YM, et al. Thymic stromal lymphopoietin is induced by respiratory syncytial virus-infected airway epithelial cells and promotes a type 2 response to infection. J Allergy Clin Immunol 2012; 130: 1187-96.
46. Halfhide CP, Flanagan BF, Brearey SP, et al. Respiratory syncytial virus binds and undergoes transcription in neutrophils from the blood and airways of infants with severe bronchiolitis. J Infect Dis 2011; 204: 451-58.
47. Rosenberg HF, Dyer KD, Domachowske JB. Respiratory viruses and eosinophils: exploring the connections. Antiviral Res 2009; 83: 1-9.
48. Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011; 239: 149-66.
49. Moghaddam A, Olszewska W, Wang B, et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006; 12: 905-07.
50. Geevarghese B, Simoes EA. Antibodies for prevention and treatment of respiratory syncytial virus infections in children. Antivir Ther 2012; 17 (1 pt B): 201-11.
51. Palmenberg AC, Spiro D, Kuzmickas R, et al. Sequencing and analyses of all known human rhinovirus genomes reveal structure and evolution. Science 2009; 324: 55-59.
52. Lemanske RF Jr, Jackson DJ, Gangnon RE, et al. Rhinovirus illnesses during infancy predict subsequent childhood wheezing. J Allergy Clin Immunol 2005; 116: 571-77.
53. Papadopoulos NG, Moustaki M, Tsolia M, et al. Association of rhinovirus infection with increased disease severity in acute bronchiolitis. Am J Respir Crit Care Med 2002; 165: 1285-89.
54. Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med 2008; 178: 667-72.
55. Gern JE. Rhinovirus and the initiation of asthma. Curr Opin Allergy Clin Immunol 2009; 9: 73-78.
56. Kusel MM, de Klerk NH, Kebadze T, et al. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol 2007; 119: 1105-10.
57. Wos M, Sanak M, Soja J, Olechnowicz H, Busse WW, Szczeklik A. The presence of rhinovirus in lower airways of patients with bronchial asthma. Am J Respir Crit Care Med 2008; 177: 1082-89.
58. Corne JM, Marshall C, Smith S, et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet 2002; 359: 831-34.
59. Edwards MR, Johnston SL. Deficient interferon in virus-induced asthma exacerbations. Clin Exp Allergy 2008; 38: 1416-18.
60. Message SD, Laza-Stanca V, Mallia P, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci USA 2008; 105: 13562-67.
61. Medina RA, Garcia-Sastre A. Influenza A viruses: new research developments. Nat Rev Microbiol 2011; 9: 590-603.
62. Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360: 2605-15.
63. Shinde V, Bridges CB, Uyeki TM, et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009; 360: 2616-25.
64. Wijngaard CC, Asten L, Koopmans MP, et al. Comparing pandemic to seasonal influenza mortality: moderate impact overall but high mortality in young children. PLoS One 2012; 7: e31197.
65. Dunning J, Openshaw PJ. Impact of the 2009 influenza pandemic. Thorax 2010; 65: 471-72.
66. Nguyen-Van-Tam JS, Openshaw PJ, Hashim A, et al. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax 2010; 65: 645-51.
67. Van Kerkhove MD, Vandemaele KA, Shinde V, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 2011; 8: e1001053.
68. Everitt AR, Clare S, Pertel T, et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 2012; 484: 519-23.
69. Teijaro JR, Walsh KB, Cahalan S, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 2011; 146: 980-91.
70. Walsh KB, Teijaro JR, Rosen H, Oldstone MB. Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm. Immunol Res 2011; 51: 15-25.
71. Morse SS, Mazet JA, Woolhouse M, et al. Prediction and prevention of the next pandemic zoonosis. Lancet 2012; 380: 1956-65.
72. Wills-Karp M, Nathan A, Page K, Karp CL. New insights into innate immune mechanisms underlying allergenicity. Mucosal Immunol 2010; 3: 104-10.
73. Trompette A, Divanovic S, Visintin A, et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature 2009; 457: 585-88.
74. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med 2009; 15: 410-16.
75. Hsu SC, Chen CH, Tsai SH, et al. Functional interaction of common allergens and a C-type lectin receptor, dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN), on human dendritic cells. J Biol Chem 2010; 285: 7903-10.
76. Ege MJ, Mayer M, Normand AC, et al. Exposure to environmental microorganisms and childhood asthma. N Engl J Med 2011;364: 701-09.
77. Heederik D, von Mutius E. Does diversity of environmental microbial exposure matter for the occurrence of allergy and asthma? J Allergy Clin Immunol 2012; 130: 44-50.
78. Havstad S, Wegienka G, Zoratti EM, et al. Effect of prenatal indoor pet exposure on the trajectory of total IgE levels in early childhood. J Allergy Clin Immunol 2011; 128: 880-85.
79. Woodcock A, Forster L, Matthews E, et al. Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma. N Engl J Med 2003; 349: 225-36.
80. Knutsen AP, Bush RK, Demain JG, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol 2012; 129: 280-91.
81. Pulimood TB, Corden JM, Bryden C, Sharples L, Nasser SM. Epidemic asthma and the role of the fungal mold Alternaria alternata. J Allergy Clin Immunol 2007; 120: 610-17.
82. Denning DW, O'Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009; 179: 11-18.
83. Lambrecht BN, Hammad H. The airway epithelium in asthma. Nat Med 2012; 18: 684-92.
84. Xiao C, Puddicombe SM, Field S, et al. Defective epithelial barrier function in asthma. J Allergy Clin Immunol 2011; 128: 549-56.
85. Holtzman MJ, Patel DA, Zhang Y, Patel AC. Host epithelial-viral interactions as cause and cure for asthma. Curr Opin Immunol 2011; 23: 487-94.
86. Forbes RL, Gibson PG, Murphy VE, Wark PA. Impaired type I and III interferon response to rhinovirus infection during pregnancy and asthma. Thorax 2012; 67: 209-14.
87. Sykes A, Edwards MR, Macintyre J, et al. Rhinovirus 16-induced IFN-alpha and IFN-beta are deficient in bronchoalveolar lavage cells in asthmatic patients. J Allergy Clin Immunol 2012; 129: 1506-14.
88. Baraldo S, Contoli M, Bazzan E, et al. Deficient antiviral immune responses in childhood: Distinct roles of atopy and asthma. J Allergy Clin Immunol 2012; 130: 1307-14.
89. Lambrecht BN, Hammad H. The role of dendritic and epithelial cells as master regulators of allergic airway inflammation. Lancet 2010; 376: 835-43.
90. Hanabuchi S, Watanabe N, Liu YJ. TSLP and immune homeostasis. Allergol Int 2012; 61: 19-25.
91. Wills-Karp M, Rani R, Dienger K, et al. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection. J Exp Med 2012; 209: 607-22.
92. Bonilla WV, Frohlich A, Senn K, et al. The alarmin interleukin-33 drives protective antiviral CD8 T cell responses. Science 2012; 335: 984-89.
93. Islam SA, Luster AD. T cell homing to epithelial barriers in allergic disease. Nat Med 2012; 18: 705-15.
94. McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012; 185: 612-19.
95. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651-59.
96. Choy DF, Modrek B, Abbas AR, et al. Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways. J Immunol 2011; 186: 1861-69.
97. Spits H, Artis D, Colonna M, et al. Innate lymphoid cells-a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13: 145-49.
98. Hams E, Fallon PG. Innate type 2 cells and asthma. Curr Opin Pharmacol 2012; 12: 503-09.
99. Byers DE, Holtzman MJ. Alternatively activated macrophages and airway disease. Chest 2011; 140: 768-74.
100. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med 2012; 18: 693-704.
101. Hogan SP, Rosenberg HF, Moqbel R, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008; 38: 709-50.
102. Fahy JV. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies. Proc Am Thorac Soc 2009; 6: 256-59.
103. Holgate ST. Innate and adaptive immune responses in asthma. Nat Med 2012; 18: 673-83.
104. Habibzay M, Saldana JI, Goulding J, Lloyd CM, Hussell T. Altered regulation of Toll-like receptor responses impairs antibacterial immunity in the allergic lung. Mucosal Immunol 2012; 5: 524-34.
105. Slater L, Bartlett N W, Haas JJ, et al. Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epithelium. PLoS Pathog 2010; 6: e1001178.
106. Connolly DJ, O'Neill LA. New developments in Toll-like receptor targeted therapeutics. Curr Opin Pharmacol 2012; 12: 510-18.
107. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716-25.
108. Gupta A, Bush A, Hawrylowicz C, Saglani S. Vitamin d and asthma in children. Paediatr Respir Rev 2012; 13: 236-43.
109. Folsgaard NV, Chawes BL, Bonnelykke K, Jenmalm MC, Bisgaard H. Cord blood Th2-related chemokine CCL22 levels associate with elevated total-IgE during preschool age. Clin Exp Allergy 2012; 42: 1596-603.
110. Abrahamsson TR, Sandberg AM, Forsberg A, Bjorksten B, Jenmalm MC. A Th1/Th2-associated chemokine imbalance during infancy in children developing eczema, wheeze and sensitization. Clin Exp Allergy 2011; 41: 1729-39.
111. Sumino K, Tucker J, Shahab M, et al. Antiviral IFN-gamma responses of monocytes at birth predict respiratory tract illness in the first year of life. J Allergy Clin Immunol 2012; 129: 1267-73.
112. Ho SM. Environmental epigenetics of asthma: an update. J Allergy Clin Immunol 2010; 126: 453-65.
113. Abrahamsson TR, Sinkiewicz G, Jakobsson T, Fredrikson M, Bjorksten B. Probiotic lactobacilli in breast milk and infant stool in relation to oral intake during the first year of life. J Pediatr Gastroenterol Nutr 2009; 49: 349-54.
114. Bisgaard H, Hermansen MN, Buchvald F, et al. Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med 2007; 357: 1487-95.
115. Folsgaard NV, Chawes BL, Rasmussen MA, et al. Neonatal cytokine profile in the airway mucosal lining fluid is skewed by maternal atopy. Am J Respir Crit Care Med 2012; 185: 275-80.
116. Wright M, Piedimonte G. Respiratory syncytial virus prevention and therapy: past, present, and future. Pediatr Pulmonol 2011; 46: 324-47.
117. Chawes BL, Poorisrisak P, Johnston SL, Bisgaard H. Neonatal bronchial hyperresponsiveness precedes acute severe viral bronchiolitis in infants. J Allergy Clin Immunol 2012; 130: 354-61.
118. Brand PL, Baraldi E, Bisgaard H, et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur Respir J 2008; 32: 1096-110.
119. Tan RA, Corren J. The relationship of rhinitis and asthma, sinusitis, food allergy, and eczema. Immunol Allergy Clin North Am 2011;31: 481-91.
120. Bush A, Menzies-Gow A. Phenotypic differences between pediatric and adult asthma. Proc Am Thorac Soc 2009; 6: 712-19.
121. Huang YJ, Nelson CE, Brodie EL, et al. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol 2011; 127: 372-81.
122. Jones SC, Iverson D, Burns P, Evers U, Caputi P, Morgan S. Asthma and ageing: an end user's perspective-the perception and problems with the management of asthma in the elderly. Clin Exp Allergy 2011; 41: 471-81.
123. Kraft M. Asthma phenotypes and interleukin-13-moving closer to personalized medicine. N Engl J Med 2011; 365: 1141-44.
124. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139: 28-35.
125. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-93.
126. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-84.
127. Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba GP. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 2012; 42: 712-37.
128. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-98.
129. Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol 2012; 130: 829-42.
130. Nicholson GC, Kariyawasam HH, Tan AJ, et al. The effects of an anti-IL-13 mAb on cytokine levels and nasal symptoms following nasal allergen challenge. J Allergy Clin Immunol 2011; 128: 800-07.
131. Boulet LP, Gauvreau G, Boulay ME, O'Byrne P, Cockcroft DW. The allergen bronchoprovocation model: an important tool for the investigation of new asthma anti-inflammatory therapies. Allergy 2007; 62: 1101-10.
132. O'Byrne PM, Gauvreau GM, Brannan JD. Provoked models of asthma: what have we learnt? Clin Exp Allergy 2009; 39: 181-92.
133. Pollard AJ, Savulescu J, Oxford J, et al. Human microbial challenge: the ultimate animal model. Lancet Infect Dis 2012; 12: 903-05.
134. DeMore JP, Weisshaar EH, Vrtis RF, et al. Similar colds in subjects with allergic asthma and nonatopic subjects after inoculation with rhinovirus-16. J Allergy Clin Immunol 2009; 124: 245-52.
135. DeVincenzo JP, Wilkinson T, Vaishnaw A, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 2010; 182: 1305-14.
136. Jones S, Evans K, McElwaine-Johnn H, et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009; 27: 2506-12.
137. Hernandez ML, Herbst M, Lay JC, et al. Atopic asthmatic patients have reduced airway inflammatory cell recruitment after inhaled endotoxin challenge compared with healthy volunteers. J Allergy Clin Immunol 2012; 130: 869-76.
138. Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 2009; 461: 218-23.
139. Schadt EE, Bjorkegren JL. NEW: network-enabled wisdom in biology, medicine, and health care. Sci Transl Med 2012; 4: 115rv1.
140. Auffray C, Adcock IM, Chung KF, Djukanovic R, Pison C, Sterk PJ. An integrative systems biology approach to understanding pulmonary diseases. Chest 2010; 137: 1410-16.
141. Szefler SJ, Dakhama A. New insights into asthma pathogenesis and treatment. Curr Opin Immunol 2011; 23: 801-07.